4.8 Article

Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair

Journal

MOLECULAR CELL
Volume 64, Issue 4, Pages 704-719

Publisher

CELL PRESS
DOI: 10.1016/j.molcel.2016.09.032

Keywords

-

Funding

  1. Medical Research Council [MC_PC_12001/1]
  2. University of Oxford
  3. John Fell Fund [133/075]
  4. Wellcome Trust [097813/Z/11/Z, 106169/ZZ14/Z]
  5. Kennedy Trust
  6. NHMRC [GNT1032364]
  7. Victorian State Government
  8. Australian Government NHMRC IRIISS
  9. SGC - AbbVie [1097737]
  10. Bayer Pharma AG
  11. Boehringer Ingelheim
  12. Canada Foundation for Innovation
  13. Eshelman Institute for Innovation
  14. Genome Canada
  15. Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD) [115766]
  16. Janssen
  17. Merck Co.
  18. Novartis Pharma AG
  19. Ontario Ministry of Economic Development and Innovation
  20. Pfizer
  21. Sao Paulo Research Foundation-FAPESP
  22. Takeda
  23. Wellcome Trust [097813/Z/11/Z] Funding Source: Wellcome Trust
  24. MRC [MC_PC_12001/1] Funding Source: UKRI
  25. Medical Research Council [MC_PC_12001/1] Funding Source: researchfish

Ask authors/readers for more resources

The cytotoxicity of DNA-protein crosslinks (DPCs) is largely ascribed to their ability to block the progression of DNA replication. DPCs frequently occur in cells, either as a consequence of metabolism or exogenous agents, but the mechanism of DPC repair is not completely understood. Here, we characterize SPRTN as a specialized DNA-dependent and DNA replication-coupled metalloprotease for DPC repair. SPRTN cleaves various DNA binding substrates during S-phase progression and thus protects proliferative cells from DPC toxicity. Ruijs-Aalfs syndrome (RJALS) patient cells with monogenic and biallelic mutations in SPRTN are hypersensitive to DPCinducing agents due to a defect in DNA replication fork progression and the inability to eliminate DPCs. We propose that SPRTN protease represents a specialized DNA replication-coupled DPC repair pathway essential for DNA replication progression and genome stability. Defective SPRTN-dependent clearance of DPCs is the molecular mechanism underlying RJALS, and DPCs are contributing to accelerated aging and cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available